Position in CYTK
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$1,014,527
+$12,102 QoQ
Shares Held
11,909
-21.7% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#262
of 477 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GABELLI FUNDS LLC holds $57,798,048 across 32 Biotechnology names. CYTK ranks #11 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
127,281 | $16,894,007 | |
| 2 | TECH |
BIO-TECHNE Corp
|
189,300 | $13,374,045 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
65,300 | $4,863,544 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,891 | $3,919,696 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
46,200 | $3,616,074 | |
| 6 | MRNA |
Moderna, Inc.
|
29,500 | $2,065,885 | |
| 7 | INCY |
Incyte Corp
|
14,197 | $1,609,371 | |
| 8 | ABVX |
Abivax S.A.
|
10,000 | $1,332,600 |
All Filings in CYTK
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,014,527 | 11,909 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $1,002,425 | 15,209 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $902,839 | 14,209 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $1,910,354 | 34,759 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $277,866 | 8,410 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $261,235 | 6,500 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $235,200 | 5,000 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $285,120 | 5,400 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $270,900 | 5,000 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $350,550 | 5,000 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||